Synonyms: JNJ-64007957 | teclistamab-cqyv | Tecvayli®
teclistamab is an approved drug (EMA & FDA (2022))
Compound class:
Antibody
Comment: Teclistamab (JNJ-64007957) is a bispecific IgG4 monoclonal antibody that simultaneously engages CD3 on the surface of T cells, and B-cell maturation antigen (BCMA) that is expressed on the surface of multiple myeloma (MM) cells, to induce a T cell-mediated cytotoxic immune response against the BCMA +ve cells [2].
|
Classification | |
Compound class | Antibody |
Approved drug? | Yes (EMA & FDA (2022)) |
International Nonproprietary Names | |
INN number | INN |
10928 | teclistamab |
Synonyms |
JNJ-64007957 | teclistamab-cqyv | Tecvayli® |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 894 |
Other databases | |
GtoPdb PubChem SID | 473153821 |
Search PubMed clinical trials | teclistamab |
Search PubMed titles | teclistamab |
Search PubMed titles/abstracts | teclistamab |